Brodalumab (Kyntheum®)

Assessment Status Rapid Review complete
Drug Brodalumab
Brand Kyntheum®
Indication Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 25/07/2017
Rapid review completed 29/08/2017
Rapid review outcome Full pharmacoeconomic assessment recommended at submitted price

The HSE has approved reimbursement following confidential price negotiations January 2018.